vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and TON Strategy Co (TONX). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $5.7M, roughly 1.7× TON Strategy Co). Cellectis S.A. runs the higher net margin — -265.9% vs -3968.6%, a 3702.7% gap on every dollar of revenue. On growth, TON Strategy Co posted the faster year-over-year revenue change (694.2% vs 375.0%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-8.0M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
CLLS vs TONX — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $5.7M |
| Net Profit | $-25.3M | $-227.9M |
| Gross Margin | — | 64.3% |
| Operating Margin | -181.1% | -159.2% |
| Net Margin | -265.9% | -3968.6% |
| Revenue YoY | 375.0% | 694.2% |
| Net Profit YoY | -51.9% | -7047.9% |
| EPS (diluted) | $-0.28 | $-3.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.7M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $2.1M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $723.0K | ||
| Q2 24 | $9.5M | — | ||
| Q3 23 | $1.6M | — | ||
| Q2 23 | $2.0M | — |
| Q4 25 | — | $-227.9M | ||
| Q3 25 | — | $84.3M | ||
| Q2 25 | — | $-2.4M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | — | $-3.2M | ||
| Q2 24 | $-25.3M | — | ||
| Q3 23 | $-17.5M | — | ||
| Q2 23 | $-16.6M | — |
| Q4 25 | — | 64.3% | ||
| Q3 25 | — | 75.4% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 73.4% | ||
| Q4 24 | — | 81.5% | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 97.3% | — |
| Q4 25 | — | -159.2% | ||
| Q3 25 | — | -601.5% | ||
| Q2 25 | — | -138.2% | ||
| Q1 25 | — | -203.8% | ||
| Q4 24 | — | -513.1% | ||
| Q2 24 | -181.1% | — | ||
| Q3 23 | -1258.1% | — | ||
| Q2 23 | -1180.5% | — |
| Q4 25 | — | -3968.6% | ||
| Q3 25 | — | 2336.8% | ||
| Q2 25 | — | -111.9% | ||
| Q1 25 | — | -196.5% | ||
| Q4 24 | — | -440.9% | ||
| Q2 24 | -265.9% | — | ||
| Q3 23 | -1064.1% | — | ||
| Q2 23 | -831.6% | — |
| Q4 25 | — | $-3.89 | ||
| Q3 25 | — | $2.23 | ||
| Q2 25 | — | $-1.79 | ||
| Q1 25 | — | $-2.51 | ||
| Q4 24 | — | $10.41 | ||
| Q2 24 | $-0.28 | — | ||
| Q3 23 | $-0.31 | — | ||
| Q2 23 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $39.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $406.5M |
| Total Assets | $407.1M | $411.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $39.5M | ||
| Q3 25 | — | $53.9M | ||
| Q2 25 | — | $10.4M | ||
| Q1 25 | — | $12.2M | ||
| Q4 24 | — | $12.5M | ||
| Q2 24 | $149.0M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $84.4M | — |
| Q4 25 | — | $406.5M | ||
| Q3 25 | — | $639.1M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $14.6M | ||
| Q4 24 | — | $16.2M | ||
| Q2 24 | $148.6M | — | ||
| Q3 23 | $76.1M | — | ||
| Q2 23 | $96.6M | — |
| Q4 25 | — | $411.2M | ||
| Q3 25 | — | $661.9M | ||
| Q2 25 | — | $23.7M | ||
| Q1 25 | — | $18.4M | ||
| Q4 24 | — | $20.6M | ||
| Q2 24 | $407.1M | — | ||
| Q3 23 | $209.7M | — | ||
| Q2 23 | $227.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-8.0M |
| Free Cash FlowOCF − Capex | $27.6M | $-8.0M |
| FCF MarginFCF / Revenue | 290.5% | -139.3% |
| Capex IntensityCapex / Revenue | 13.2% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.0M | ||
| Q3 25 | — | $-9.4M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q2 24 | $28.9M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.4M | — |
| Q4 25 | — | $-8.0M | ||
| Q3 25 | — | $-9.4M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-2.0M | ||
| Q2 24 | $27.6M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.9M | — |
| Q4 25 | — | -139.3% | ||
| Q3 25 | — | -261.4% | ||
| Q2 25 | — | -107.8% | ||
| Q1 25 | — | -87.0% | ||
| Q4 24 | — | -279.9% | ||
| Q2 24 | 290.5% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -2391.4% | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 22.1% | ||
| Q2 24 | 13.2% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 24.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLLS
Segment breakdown not available.
TONX
| Market Live | $4.8M | 83% |
| Other | $960.0K | 17% |
